Results 201 to 210 of about 17,442 (284)

Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG. [PDF]

open access: yesCirc Cardiovasc Interv
Dillen DMM   +15 more
europepmc   +1 more source

Medicaid Expansion Among Nonelderly Adults and Cardiovascular Disease: Efficiency Vs. Equity

open access: yesThe Milbank Quarterly, EarlyView.
Policy Points Evidence suggests Medicaid expansion has improved cardiovascular disease (CVD) outcomes, especially among those of lower socioeconomic status. However, less is known about the cost‐effectiveness of Medicaid in achieving these outcomes and reducing CVD disparities.
LUKE E. BARRY   +3 more
wiley   +1 more source

Exercise‐Induced Cardiac Lymphatic Remodeling Mitigates Inflammation in the Aging Heart

open access: yesAging Cell, EarlyView.
Exercise improves cardiac lymphatic architecture and function in the aged mouse. Aged hearts show reduced lymphatic vascular density, more dilated vessels, and increased peri‐lymphatic inflammation and fibrosis. Exercise training of the aged mouse increases lymph vessel density and sprouting, reverses their dilation, reduces inflammation and fibrosis ...
Kangsan Roh   +19 more
wiley   +1 more source

Perioperative Mechanical Circulatory Support for Cardiac Assistance in Thoracic Surgery: A Scoping Review

open access: yesArtificial Organs, EarlyView.
High‐risk cardiac patients may benefit from timely temporary mechanical circulatory support (tMCS) implantation to provide perioperative hemodynamic stabilization and circulatory support, thus enabling them to undergo life‐saving thoracic surgery. CPB: cardiopulmonary bypass; IABP: intra‐aortic balloon pump; tMCS: temporary mechanical circulatory ...
Viviana Teresa Agosta   +4 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy